Fitusiran - Alnylam Pharmaceuticals

Drug Profile

Fitusiran - Alnylam Pharmaceuticals

Alternative Names: ALN AT3; ALN-AT3SC; SAR 439774

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Sanofi Genzyme
  • Class Antifibrinolytics; Antihaemorrhagics; Antisense RNA; Drug conjugates; Small interfering RNA
  • Mechanism of Action Antithrombin III inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A; Haemophilia B

Most Recent Events

  • 08 Sep 2017 Adverse events data from a phase II trial in Haemophilia A and Haemophilia B released by Alnylam
  • 07 Sep 2017 Alnylam suspends planned dosing of patients in the phase III ATLAS-PPX trial in Haemophilia A and Haemophilia B (In adolescents, In adults, In the elderly) in Spain due to a fatal thrombotic event (SC) (EudraCT2016-004087-19)
  • 07 Sep 2017 Alnylam suspends planned dosing of patients in the phase III ATLAS-A/B trial in Haemophilia A and Haemophilia B (In adolescents, In adults, In the elderly) in Ireland due to a fatal thrombotic event (SC) (EudraCT2016-001464-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top